DOCSLIB.ORG

Ptmscan® Results, Phospho-PKA Substrate Motif (RRXS*/T*)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ptmscan® Results, Phospho-PKA Substrate Motif (RRXS*/T*) Table: PTMScan® Results, Phospho-PKA Substrate Motif (RRXS*/T*), label-free quantitation Study design: rat cell line PC-12; Trypsin digest; Antibody: Phospho-PKA Substrate Motif (RRXS*/T*), PTMScan® Kit #1984, #5565 Treatments: Untreated, forskolin treated Fold-Change Index (Forskolin/Untreated) Protein Name Phosphorylation Site Description Peptide Accession kD Count in Study Intensity (Untreated) 3 Adaptor/scaffold 4 10.4 AHNAK 159 PREDICTED: similar to AHNAK nucleoprotein isoform 1 isoform 1 RVtAYTVDVTGR XP_574618 581 2 8.69E+05 5 11.2 AHNAK 161 PREDICTED: similar to AHNAK nucleoprotein isoform 1 isoform 1 RVTAyTVDVTGREGVKDIDISSPE XP_574618 581 1 6.14E+04 6 2.8 AKAP1 101 A-kinase anchor protein 1 RRsESSGNLPSIVDTR O88884 92 1 2.49E+06 7 2.2 AKAP2 850 A kinase (PRKA) anchor protein 2 RKsALALRWE Q5U301 96 1 5.57E+05 8 6.7 AP3D1 754, 758, 760 adaptor-related protein complex 3, delta 1 subunit RHsSLPtEsDEDIAPAQRVDIITE XP_234908 136 1 5.47E+04 9 3.2 AP3D1 754, 760 adaptor-related protein complex 3, delta 1 subunit RHsSLPTEsDEDIAPAQRVDIITE XP_234908 136 1 3.61E+05 10 -6.2 CTNND1 320 catenin (cadherin associated protein), delta 1 LRsYEDM#IGEEVPPDQYYWAPLAQHE XP_001064294 105 1 5.76E+05 11 3.8 DOCK1 1756 dedicator of cyto-kinesis 1 RFsVSPASPCSQPTPPPVTPR NP_001137330 215 1 1.01E+06 12 1.7 FNBP1L 488 formin binding protein 1-like RHsSDINHLVTQGRESPE Q2HWF0 70 1 3.98E+05 13 -1.2 FRS2 132, 135, 138 fibroblast growth factor receptor substrate 2 LEVPRtPRtPTtPGLGAQSLPNGYPR EDM16633 57 2 2.59E+05 14 2.2 FRS2 428 fibroblast growth factor receptor substrate 2 DCTPTVFNFDIRRPsLE EDM16633 57 1 8.14E+05 15 3.2 IRS-2 557 PREDICTED: similar to Insulin receptor substrate 2 (IRS-2) (4PS) RVsGDGAQDLDR O70360 137 1 1.75E+05 16 2.4 MPDZ 1802 multiple PDZ domain protein IKAAPFHSERRPsQSSQVSE O55164 219 1 2.14E+06 17 1.4 MPDZ 1802, 1804, 1808 multiple PDZ domain protein IKAAPFHSERRPsQsSQVsE O55164 219 1 5.29E+05 18 2.3 MPDZ 1804, 1805 multiple PDZ domain protein AAPFHSERRPSQssQVSE O55164 219 1 5.37E+05 19 4.5 MTSS1 307 metastasis suppressor 1 KSsVCSSLNSVNSSDSR NP_001124035 86 1 2.74E+05 20 9.5 Nck1 21 NCK adaptor protein 1 RKPsVPDTASPADDSFVDPGER XP_217246 36 3 2.51E+05 21 2.1 PARD3 715 partitioning-defective protein 3 homolog RIsHSLYSGIE Q9Z340 149 1 3.76E+05 22 2.2 LIM 228 PDZ and LIM domain 5 RGsQGDIKQQNGPPR Q62920 63 4 2.01E+06 23 3.4 tensin 3 648 PREDICTED: similar to tensin-like SH2 domain containing 1 KPsAPTPTQAYGQSNYSTQTWVR XP_341257 117 1 1.16E+05 26 23.6 14-3-3 zeta 58 tyr 3-monooxygenase/tryp 5-monooxygenase activation prot, zeta polypep RSsWRVVSSIEQKTE P63102 28 2 2.02E+05 27 Adhesion or extracellular matrix protein 28 2.5 CTNNB1 552 beta-catenin RTsMGGTQQQFVE Q9WU82 85 2 2.91E+06 29 1.1 desmoplakin 174 PREDICTED: similar to desmoplakin isoform II isoform 1 RAsSKGGYTCQSGSGWDE Q4QQR7 332 2 5.62E+06 30 -2.6 desmoplakin 174, 175 PREDICTED: similar to desmoplakin isoform II isoform 1 RAssKGGYTCQSGSGWDE Q4QQR7 332 1 2.60E+05 31 1.2 desmoplakin 175 PREDICTED: similar to desmoplakin isoform II isoform 1 VRRASsKGGYTCQSGSGWDE Q4QQR7 332 1 4.87E+06 32 1.8 desmoplakin 56 PREDICTED: similar to desmoplakin isoform II isoform 1 RCtVNDQNSDGYCQTGTM#SR Q4QQR7 332 1 1.18E+05 33 -2.3 LAD1 62 ladinin SVERLPsVEEAE NP_001101412 57 1 1.17E+06 34 -1.4 Nogo iso2; Nogo 107; 107 Reticulon-4 GPLPAAPPAAPERQPsWE Q9JK11-2; Q9JK11 39; 126 2 1.92E+07 35 10.7 plakophilin 3 159 plakophilin 3 RLsSAHNGGSAFGAVGYGGAQPTPPM#PTRPVSFHE NP_001099785 90 4 6.07E+05 36 1.2 plakophilin 3 159, 188 plakophilin 3 RLsSAHNGGSAFGAVGYGGAQPTPPM#PTRPVsFHE NP_001099785 90 1 5.02E+05 37 Apoptosis 38 9.9 EI24 46 etoposide induced 2.4 mRNA RAsSLLAQR Q4KM77 39 1 1.31E+05 39 1.3 PAR-4 155 PRKC, apoptosis, WT1, regulator RStGVVNIPAAECLDEYEDDE Q62627 36 1 6.74E+05 40 -2.7 PEA-15 116 phosphoprotein enriched in astrocytes 15A YKDIIRQPsEEE Q5U318 15 1 1.54E+06 41 Cell cycle regulation 42 3.7 AFAP1L2 341 PREDICTED: similar to Protein KIAA1914 KKsTSLEPPDRSLE XP_217643 92 1 4.05E+05 43 3.4 CLASP1 600 rCG37592 SRsDIDVNAAASAK EDL87905 167 2 1.02E+06 44 6.0 CLASP1 658 rCG37593 TRRQsSGSTTNVASTSSDSR EDL87905 167 5 2.93E+05 45 6.0 CLASP1 658, 661 rCG37594 RQsSGsTTNVASTSSDSR EDL87905 167 1 8.97E+04 46 2.4 CLASP1 690 rCG37595 sSSPGKLLGSGYGGLAGGSSRGPPVTPSSE EDL87905 167 1 9.95E+05 47 3.9 CLASP1 692 rCG37596 SSsPGKLLGSGYGGLAGGSSR EDL87905 167 1 2.38E+05 48 7.7 B99 501 G-2 and S-phase expressed 1 RLsGLTPQGLPSSM#R XP_217016 80 2 1.78E+05 49 1.6 KAB1 968 rCG20491, isoform CRA_b IRQPsIDLTDDDQTSSVPHSAISDIMSSDQE EDL94780 170 1 2.35E+05 50 -1.1 NuMA-1 337 PREDICTED: similar to nuclear mitotic apparatus protein 1 isoform 1 RRtTQIINITMTK Q4G051 71 1 4.21E+05 51 5.0 NUSAP1 113 nucleolar and spindle associated protein 1 RRDsTTFQNQE NP_001101232 43 3 9.67E+05 52 2.5 NUSAP1 115 nucleolar and spindle associated protein 1 M#KRRDSTtFQNQE NP_001101232 43 1 4.79E+04 53 2.4 MCC 354 PREDICTED: mutated in colorectal cancers KKsSCSLSVAE XP_225962 112 1 4.00E+05 54 2.6 MCC 354, 355 PREDICTED: mutated in colorectal cancers KKssCSLSVAE XP_225962 112 1 6.54E+05 55 3.9 SPECC1L 833 SPECC1-like RSsTSSEPTPTVK Q2KN99 124 3 3.30E+06 56 14.1 SPECC1L 833, 836 SPECC1-like RSsTSsEPTPTVK Q2KN99 124 1 4.98E+04 1 LEGEND: * = phosphorylation; # = oxidized methionine, fold changes greater than 5 upon drug treatment are highlighted Table: PTMScan® Results, Phospho-PKA Substrate Motif (RRXS*/T*), label-free quantitation Study design: rat cell line PC-12; Trypsin digest; Antibody: Phospho-PKA Substrate Motif (RRXS*/T*), PTMScan® Kit #1984, #5565 Treatments: Untreated, forskolin treated Fold-Change Index (Forskolin/Untreated) Protein Name Phosphorylation Site Description Peptide Accession kD Count in Study Intensity (Untreated) 57 Chaperone 58 12.1 HSP20 16 heat shock protein, alpha-crystallin-related, B6 RAsAPLPGFSTPGR P97541 18 1 3.86E+05 59 Chromatin, DNA-binding, DNA repair or DNA replication protein 60 1.9 capicua 1394, 1405 capicua homolog KNsTDLDSAPEDPtSPKRK NP_001100960 164 2 1.06E+06 61 45.7 H1C 36 histone cluster 1, H1d KAsGPPVSE P15865 22 9 1.08E+05 62 -1.7 LBR 101 lamin B receptor SVsASYQADAKEKE O08984 71 1 2.70E+05 63 2.9 polybromo 1 39 PREDICTED: similar to polybromo 1 isoform 2 isoform 1 RLsSLPTVDPIAVCHE XP_001059112 181 1 9.24E+05 64 4.0 TERF2IP 43 telomeric repeat binding factor 2, interacting protein RLsTLILHGGGILCR Q5EAN7 43 1 4.59E+05 65 5.8 TTF1 103 PREDICTED: similar to transcription termination factor 1 RREsQTPAQENLE XP_001079280 96 1 8.21E+04 66 Cytoskeletal protein 67 51.5 cordon-bleu 1042 cordon-bleu homolog KVsSLASEE NP_001100706 122 1 5.88E+04 68 -1.6 cordon-bleu 219 cordon-bleu homolog KSsLGNDETDKE NP_001100706 122 2 1.02E+04 69 3.3 cordon-bleu 648 cordon-bleu homolog RNsMEKYLNGPAE NP_001100706 122 1 4.21E+05 70 7.9 DAL-1 423 erythrocyte protein band 4.1-like 3 RAsALIDRPAPYFE Q9JMB3 122 1 2.41E+05 71 1.9 EPPK1 2290, 2709, 3224 PREDICTED: similar to Epiplakin AQAATGFIIDPVHNRRLsVEE XP_001059215 370 1 6.03E+05 72 6.4 FLNB 2107 filamin, beta TSRAPsVATVGSICD XP_224561 278 1 2.27E+05 73 1.5 FNBP1 496 formin binding protein 1 RQsGLYDGQTHQTVTNCAQDRE Q8R511 71 2 1.65E+05 74 3.7 KIF23 903 kinesin family member 23 RsSTLAPAQPDGTESE NP_001101625 109 1 3.07E+05 75 1.1 KIF23 903, 904 kinesin family member 23 KRRssTLAPAQPDGTESE NP_001101625 109 1 4.28E+05 76 4.7 KIF23 904 kinesin family member 23 RSsTLAPAQPDGTESEWTDVE NP_001101625 109 2 3.80E+05 77 5.7 KIF23 905 kinesin family member 23 RSStLAPAQPDGTE NP_001101625 109 2 1.32E+06 78 -7.6 K14 40 keratin 14 M#SSVLAGGSCRAPsTYGGM#SR Q6IFV1 53 2 1.03E+06 79 -2.8 K14 42 keratin 14 M#SSVLAGGSCRAPSTyGGMSR Q6IFV1 53 1 7.33E+05 80 -1.9 eplin 225 PREDICTED: similar to Epithelial protein lost in neoplasm (mEPLIN) RLsENSCSLDDLE Q6J4T4 84 2 1.83E+06 81 -1.1 nestin; nestin iso2 1166; 1078 nestin RKsIDTQEPLWSTE P21263; P21263-2 209; 199 1 9.61E+06 82 -1.6 plectin 1 4641, 4645 plectin 1 AGsRRGsFDATGSGFSM#TFSSSSYSSSGYGR P30427 534 1 3.22E+05 83 -3.0 plectin 1 4645 plectin 1 RGsFDATGSGFSM#TFSSSSYSSSGYGR P30427 534 2 2.12E+06 84 1.3 RIL 119 reversion induced LIM RSsISGISLE P36202 36 1 2.02E+07 85 71.4 KIF13B 1718, 1719 kinesin 13B RRssGLQPQGAPE Q70AM4 197 1 9.17E+04 86 Enzyme, misc. 87 3.7 CPOX 117 coproporphyrinogen oxidase RCsTFM#SSPVTE Q3B7D0 49 1 1.25E+05 88 2.9 GYS1 709 glycogen synthase 1 (muscle) sNSVDTGPSSSLSTPTEPLSPTSSLGEERN A2RRU1 84 1 3.79E+05 89 2.4 HELZ 1785 helicase with zinc finger domain RIsSGAAQPCVEE NP_001099318 220 1 4.35E+06 90 3.4 HMGCS1 471 hydroxymethylglutaryl-CoA synthase 1 TYARRPsTNDHSLDE P17425 57 2 3.55E+06 91 3.5 UQCRC1 214 ubiquinol-cytochrome c reductase core protein I RLSRtDLTDYLSR Q68FY0 53 1 1.45E+06 92 G protein or regulator 93 -1.0 ARF GAP1 360 ADP-ribosylation factor GTPase activating protein 1 RSsDSWDIWGSGSASNNKNSNSDGWE Q62848 45 1 6.01E+05 94 7.4 ARHGAP17 710 nadrin RCsSSLPPIQAPNHPPPQPPTQPR Q99N37 94 1 6.31E+05 95 4.7 ARHGAP17 712 nadrin RCSSsLPPIQAPNHPPPQPPTQPR Q99N37 94 1 7.61E+05 96 4.0 ARHGAP23 790 PREDICTED: similar to Rho GTPase activating protein 21 HYsQDCSSIKAGR XP_220918 177 1 1.13E+05 97 -1.1 ARHGEF5 1079 PREDICTED: similar to rho guanine nucleotide exchange factor 5 isoform 1 RCsKLINSSQLLYQE XP_342677 177 1 5.87E+05 98 6.4 ARPP-19 104 cyclic AMP phosphoprotein VTGDHIPTPQDLPQRKPsLVASKLAG Q712U5 12 10 8.48E+06 99 8.5 DOCK6 41 dedicator of cytokinesis 6 RSSsSLGVPLTE NP_001102467 202 1 8.55E+05 100 1.1 RalGAPA1 753 PREDICTED: similar to GTPase activating RANGAP domain-like 1 isoform 3 SIVRQKtVDIDDSQILPR O55007 234 1 2.95E+05 101 -1.4 RalGAPA1 772 PREDICTED: similar to GTPase activating RANGAP domain-like 1 isoform 3 VRHFsQSEDTGNE O55007 234 1 1.78E+05 102 -1.4 GIT2 614 G protein-coupled
Load more

Recommended publications
  • A Key Genomic Signature Associated with Lymphovascular Invasion in Head and Neck Squamous Cell Carcinoma
    A key genomic signature associated with lymphovascular invasion in head and neck squamous cell carcinoma Jian Zhang Aliated Cancer hospital & Institute of Guangzhou Medical University Huali Jiang Aliated Donghua Hospital of Sun Yat-sen University Tao Xie Aliated Cancer Hospital of Guangzhou Medical University Baiyao Wang Aliated Cancer Hospital of Guangzhou Medical Unversity Xiaoting Huang Aliated Cancer Hospital & Institute of Guangzhou Medical University Jie Lin Aliated Cancer Hospital & Institute of Guangzhou Medical University Anan Xu Aliated Cancer Hospital of Guangzhou Medical University Rong Li Aliated Cancer Hospital & Institute of Guangzhou Medical University Yawei Yuan ( [email protected] ) Guangzhou Medical University Aliated Cancer Hospital Research article Keywords: lymphovascular invasion, head and neck squamous cell carcinoma, hub genes, TCGA, weighted gene co-expression network analysis Posted Date: January 16th, 2020 DOI: https://doi.org/10.21203/rs.2.18349/v2 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/24 Abstract Objective: Lymphovascular invasion (LOI), a key pathological feature of head and neck squamous cell carcinoma (HNSCC), predicts poor survival. However, the associated clinical characteristics remain uncertain, and the molecular mechanisms are largely unknown. Methods: Weighted gene co-expression network analysis was performed to construct gene co-expression networks and investigate the relationship between modules and LOI clinical trait. Functional enrichment and KEGG pathway enrichment analysis were performed for differentially expressed genes using DAVID database. The protein-protein interaction network was constructed using Cytoscape software, and module analysis was performed using MCODE. Prognosis role and expression analysis was further validated by survival analysis, GEPIA analysis and HPA database.
    [Show full text]
  • Apoptotic Genes As Potential Markers of Metastatic Phenotype in Human Osteosarcoma Cell Lines
    17-31 10/12/07 14:53 Page 17 INTERNATIONAL JOURNAL OF ONCOLOGY 32: 17-31, 2008 17 Apoptotic genes as potential markers of metastatic phenotype in human osteosarcoma cell lines CINZIA ZUCCHINI1, ANNA ROCCHI2, MARIA CRISTINA MANARA2, PAOLA DE SANCTIS1, CRISTINA CAPANNI3, MICHELE BIANCHINI1, PAOLO CARINCI1, KATIA SCOTLANDI2 and LUISA VALVASSORI1 1Dipartimento di Istologia, Embriologia e Biologia Applicata, Università di Bologna, Via Belmeloro 8, 40126 Bologna; 2Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; 3IGM-CNR, Unit of Bologna, c/o Istituti Ortopedici Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy Received May 29, 2007; Accepted July 19, 2007 Abstract. Metastasis is the most frequent cause of death among malignant primitive bone tumor, usually developing in children patients with osteosarcoma. We have previously demonstrated and adolescents, with a high tendency to metastasize (2). in independent experiments that the forced expression of Metastases in osteosarcoma patients spread through peripheral L/B/K ALP and CD99 in U-2 OS osteosarcoma cell lines blood very early and colonize primarily the lung, and later markedly reduces the metastatic ability of these cancer cells. other skeleton districts (3). Since disseminated hidden micro- This behavior makes these cell lines a useful model to assess metastases are present in 80-90% of OS patients at the time the intersection of multiple and independent gene expression of diagnosis, the identification of markers of invasiveness signatures concerning the biological problem of dissemination. and metastasis forms a target of paramount importance in With the aim to characterize a common transcriptional profile planning the treatment of osteosarcoma lesions and enhancing reflecting the essential features of metastatic behavior, we the prognosis.
    [Show full text]
  • Profiling Microdissected Epithelium and Stroma to Model Genomic Signatures for Cervical Carcinogenesis Accommodating for Covariates
    Research Article Profiling Microdissected Epithelium and Stroma to Model Genomic Signatures for Cervical Carcinogenesis Accommodating for Covariates David Gius,1 Margo C. Funk,2 Eric Y. Chuang,1 Sheng Feng,3 Phyllis C. Huettner,4 Loan Nguyen,2 C. Matthew Bradbury,1 Mark Mishra,1 Shuping Gao,1 Barbara M. Buttin,2 David E. Cohn,2 Matthew A. Powell,2 Neil S. Horowitz,2 Bradford P. Whitcomb,2 and JanetS. Rader 2 1Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland and 2Division of Gynecologic Oncology, Department of Obstetrics and Gynecology; 3Division of Biostatistics; and 4Lauren V. Ackerman Laboratory of Surgical Pathology, Washington University School of Medicine, St. Louis, Missouri Abstract (CIN 1–3) and finally to squamous cell carcinoma antigen (SCCA) This study is the first comprehensive, integrated approach to have been well characterized. Histologically, CIN 1 consists of examine grade-specific changes in gene expression along the immature basal-type cells involving the lower third of the entire neoplastic spectrum of cervical intraepithelial neoplasia epithelium. In CIN 2, these immature basal-type cells involve more (CIN) in the process of cervical carcinogenesis. This was than the lower third, whereas CIN 3 involves the full thickness of the accomplished by identifying gene expression signatures of epithelium. In addition, higher CIN grades exhibit nuclear crowding, disease progression using cDNA microarrays to analyze RNA pleomorphism, loss of cell polarity, and increased mitotic activity from laser-captured microdissected epithelium and underlying (1). These transitions seemto be well conserved and, as such, stroma from normal cervix, graded CINs, cancer, and patient- provide an intriguing systemto use genomicsto identify the early matched normal cervical tissues.
    [Show full text]
  • A Dissertation Entitled the Androgen Receptor
    A Dissertation entitled The Androgen Receptor as a Transcriptional Co-activator: Implications in the Growth and Progression of Prostate Cancer By Mesfin Gonit Submitted to the Graduate Faculty as partial fulfillment of the requirements for the PhD Degree in Biomedical science Dr. Manohar Ratnam, Committee Chair Dr. Lirim Shemshedini, Committee Member Dr. Robert Trumbly, Committee Member Dr. Edwin Sanchez, Committee Member Dr. Beata Lecka -Czernik, Committee Member Dr. Patricia R. Komuniecki, Dean College of Graduate Studies The University of Toledo August 2011 Copyright 2011, Mesfin Gonit This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of The Androgen Receptor as a Transcriptional Co-activator: Implications in the Growth and Progression of Prostate Cancer By Mesfin Gonit As partial fulfillment of the requirements for the PhD Degree in Biomedical science The University of Toledo August 2011 Prostate cancer depends on the androgen receptor (AR) for growth and survival even in the absence of androgen. In the classical models of gene activation by AR, ligand activated AR signals through binding to the androgen response elements (AREs) in the target gene promoter/enhancer. In the present study the role of AREs in the androgen- independent transcriptional signaling was investigated using LP50 cells, derived from parental LNCaP cells through extended passage in vitro. LP50 cells reflected the signature gene overexpression profile of advanced clinical prostate tumors. The growth of LP50 cells was profoundly dependent on nuclear localized AR but was independent of androgen. Nevertheless, in these cells AR was unable to bind to AREs in the absence of androgen.
    [Show full text]
  • Plasma Cells in Vitro Generation of Long-Lived Human
    Downloaded from http://www.jimmunol.org/ by guest on September 24, 2021 is online at: average * The Journal of Immunology , 32 of which you can access for free at: 2012; 189:5773-5785; Prepublished online 16 from submission to initial decision 4 weeks from acceptance to publication November 2012; doi: 10.4049/jimmunol.1103720 http://www.jimmunol.org/content/189/12/5773 In Vitro Generation of Long-lived Human Plasma Cells Mario Cocco, Sophie Stephenson, Matthew A. Care, Darren Newton, Nicholas A. Barnes, Adam Davison, Andy Rawstron, David R. Westhead, Gina M. Doody and Reuben M. Tooze J Immunol cites 65 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription http://www.jimmunol.org/content/suppl/2012/11/16/jimmunol.110372 0.DC1 This article http://www.jimmunol.org/content/189/12/5773.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 24, 2021. The Journal of Immunology In Vitro Generation of Long-lived Human Plasma Cells Mario Cocco,*,1 Sophie Stephenson,*,1 Matthew A.
    [Show full text]
  • KIF23 Enhances Cell Proliferation in Pancreatic Ductal Adenocarcinoma and Is a Potent Therapeutic Target
    1394 Original Article Page 1 of 15 KIF23 enhances cell proliferation in pancreatic ductal adenocarcinoma and is a potent therapeutic target Chun-Tao Gao1#, Jin Ren2#, Jie Yu1,3#, Sheng-Nan Li1, Xiao-Fan Guo1, Yi-Zhang Zhou1 1Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China; 2Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, China; 3The First Hospital of Shanxi Medical University, Taiyuan, China Contributions: (I) Conception and design: CT Gao, J Ren; (II) Administrative support: CT Gao; (III) Provision of study materials or patients: J Yu; (IV) Collection and assembly of data: J Ren, SN Li, YZ Zhou; (V) Data analysis and interpretation: XF Guo, J Ren; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These authors contributed equally to this work. Correspondence to: Chun-Tao Gao. Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Huan-hu-xi Road, He-xi District, Tianjin 300060, China. Email: [email protected]. Background: In recent research, high expression of kinesin family member 23 (KIF23), one of the kinesin motor proteins involved in the regulation of cytokinesis, has been shown to be related to poor prognosis in glioma and paclitaxel-resistant gastric cancer, as a results of the enhancement of proliferation, migration, and invasion. In this study, we analyzed the role of KIF23 in the progression of pancreatic ductal adenocarcinoma.
    [Show full text]
  • How Does SUMO Participate in Spindle Organization?
    cells Review How Does SUMO Participate in Spindle Organization? Ariane Abrieu * and Dimitris Liakopoulos * CRBM, CNRS UMR5237, Université de Montpellier, 1919 route de Mende, 34090 Montpellier, France * Correspondence: [email protected] (A.A.); [email protected] (D.L.) Received: 5 July 2019; Accepted: 30 July 2019; Published: 31 July 2019 Abstract: The ubiquitin-like protein SUMO is a regulator involved in most cellular mechanisms. Recent studies have discovered new modes of function for this protein. Of particular interest is the ability of SUMO to organize proteins in larger assemblies, as well as the role of SUMO-dependent ubiquitylation in their disassembly. These mechanisms have been largely described in the context of DNA repair, transcriptional regulation, or signaling, while much less is known on how SUMO facilitates organization of microtubule-dependent processes during mitosis. Remarkably however, SUMO has been known for a long time to modify kinetochore proteins, while more recently, extensive proteomic screens have identified a large number of microtubule- and spindle-associated proteins that are SUMOylated. The aim of this review is to focus on the possible role of SUMOylation in organization of the spindle and kinetochore complexes. We summarize mitotic and microtubule/spindle-associated proteins that have been identified as SUMO conjugates and present examples regarding their regulation by SUMO. Moreover, we discuss the possible contribution of SUMOylation in organization of larger protein assemblies on the spindle, as well as the role of SUMO-targeted ubiquitylation in control of kinetochore assembly and function. Finally, we propose future directions regarding the study of SUMOylation in regulation of spindle organization and examine the potential of SUMO and SUMO-mediated degradation as target for antimitotic-based therapies.
    [Show full text]
  • Genomics and Functional Genomics of Malignant Pleural Mesothelioma
    International Journal of Molecular Sciences Review Genomics and Functional Genomics of Malignant Pleural Mesothelioma Ece Cakiroglu 1,2 and Serif Senturk 1,2,* 1 Izmir Biomedicine and Genome Center, Izmir 35340, Turkey; [email protected] 2 Department of Genome Sciences and Molecular Biotechnology, Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir 35340, Turkey * Correspondence: [email protected] Received: 22 July 2020; Accepted: 20 August 2020; Published: 1 September 2020 Abstract: Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the mesothelial cells lining the pleural surface of the chest wall and lung. The etiology of MPM is strongly associated with prior exposure to asbestos fibers, and the median survival rate of the diagnosed patients is approximately one year. Despite the latest advancements in surgical techniques and systemic therapies, currently available treatment modalities of MPM fail to provide long-term survival. The increasing incidence of MPM highlights the need for finding effective treatments. Targeted therapies offer personalized treatments in many cancers. However, targeted therapy in MPM is not recommended by clinical guidelines mainly because of poor target definition. A better understanding of the molecular and cellular mechanisms and the predictors of poor clinical outcomes of MPM is required to identify novel targets and develop precise and effective treatments. Recent advances in the genomics and functional genomics fields have provided groundbreaking insights into the genomic and molecular profiles of MPM and enabled the functional characterization of the genetic alterations. This review provides a comprehensive overview of the relevant literature and highlights the potential of state-of-the-art genomics and functional genomics research to facilitate the development of novel diagnostics and therapeutic modalities in MPM.
    [Show full text]
  • Microarray-Based Classification of a Consecutive Series of 121 Childhood
    Leukemia (2007) 21, 1198–1203 & 2007 Nature Publishing Group All rights reserved 0887-6924/07 $30.00 www.nature.com/leu ORIGINAL ARTICLE Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status A Andersson1, C Ritz2, D Lindgren1, P Ede´n2, C Lassen1, J Heldrup3, T Olofsson4,JRa˚de5, M Fontes5, A Porwit-MacDonald6, M Behrendtz7,MHo¨glund1, B Johansson1 and T Fioretos1 1Department of Clinical Genetics, Lund University Hospital, Lund, Sweden; 2Department of Complex System Division, Theoretical Physics, Lund University, Lund, Sweden; 3Department of Pediatrics, Lund University Hospital, Lund, Sweden; 4Department of Hematology, Lund University Hospital, Lund, Sweden; 5Center for Mathematical Sciences, Lund University, Lund, Sweden; 6Department of Pathology, Karolinska Hospital and Institute, Stockholm, Sweden and 7Department of Pediatrics, Linko¨ping University Hospital, Linko¨ping, Sweden Gene expression analyses were performed on 121 consecutive notype, white blood cell (WBC) count, central nervous system childhood leukemias (87 B-lineage acute lymphoblastic leuke- (CNS) involvement, response to therapy and genetic findings.6,7 mias (ALLs), 11 T-cell ALLs and 23 acute myeloid leukemias Despite the quite dramatic progress in treatment, risk- (AMLs)), investigated during an 8-year period at a single center. stratification and biological understanding of childhood leuke- The supervised learning algorithm k-nearest neighbor was 8 utilized to build gene expression predictors that could classify mias over recent decades, further improvements are still the ALLs/AMLs according to clinically important subtypes with needed. Refined risk assessment will hopefully result in the high accuracy.
    [Show full text]
  • The Genetic Program of Pancreatic Beta-Cell Replication in Vivo
    Page 1 of 65 Diabetes The genetic program of pancreatic beta-cell replication in vivo Agnes Klochendler1, Inbal Caspi2, Noa Corem1, Maya Moran3, Oriel Friedlich1, Sharona Elgavish4, Yuval Nevo4, Aharon Helman1, Benjamin Glaser5, Amir Eden3, Shalev Itzkovitz2, Yuval Dor1,* 1Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel 2Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. 3Department of Cell and Developmental Biology, The Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel 4Info-CORE, Bioinformatics Unit of the I-CORE Computation Center, The Hebrew University and Hadassah, The Institute for Medical Research Israel- Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel 5Endocrinology and Metabolism Service, Department of Internal Medicine, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel *Correspondence: [email protected] Running title: The genetic program of pancreatic β-cell replication 1 Diabetes Publish Ahead of Print, published online March 18, 2016 Diabetes Page 2 of 65 Abstract The molecular program underlying infrequent replication of pancreatic beta- cells remains largely inaccessible. Using transgenic mice expressing GFP in cycling cells we sorted live, replicating beta-cells and determined their transcriptome. Replicating beta-cells upregulate hundreds of proliferation- related genes, along with many novel putative cell cycle components. Strikingly, genes involved in beta-cell functions, namely glucose sensing and insulin secretion were repressed. Further studies using single molecule RNA in situ hybridization revealed that in fact, replicating beta-cells double the amount of RNA for most genes, but this upregulation excludes genes involved in beta-cell function.
    [Show full text]
  • Impaired PRC2 Activity Promotes Transcriptional Instability and Favors Breast Tumorigenesis
    Downloaded from genesdev.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis Michel Wassef,1,2,3 Veronica Rodilla,1,2,3 Aurélie Teissandier,1,4,5 Bruno Zeitouni,1,4,5 Nadege Gruel,1 Benjamin Sadacca,1 Marie Irondelle,1 Margaux Charruel,1,2,3 Bertrand Ducos,6,7,8 Audrey Michaud,1,2,3 Matthieu Caron,1,2,3 Elisabetta Marangoni,1 Philippe Chavrier,1 Christophe Le Tourneau,9,10 Maud Kamal,9 Eric Pasmant,11,12,13 Michel Vidaud,11,12,13 Nicolas Servant,1,4,5 Fabien Reyal,1 Dider Meseure,1,14 Anne Vincent-Salomon,1 Silvia Fre,1,2,3 and Raphaël Margueron1,2,3 1Institut Curie, Paris Sciences et Lettres Research University, 75005 Paris, France; 2U934, Institut National de la Santé et de la Recherche Médicale, 75005 Paris, France; 3UMR3215, Centre National de la Recherche Scientifique, 75005 Paris, France; 4U900, Institut National de la Santé et de la Recherche Médicale, 75005 Paris, France; 5Mines ParisTech, 77300 Fontainebleau, France; 6Laboratoire de Physique Statistique-Ecole Normale Supérieure de Paris, Centre National de la Recherche Scientifique, 75005 Paris, France; 7UMR 8550, Centre National de la Recherche Scientifique, 75005 Paris, France; 8Plateforme de PCR Quantitative à Haut Débit Genomic Paris Centre, Institut de Biologie de l’École Normale Supérieure, 75005 Paris, France; 9Department of Medical Oncology, Institut Curie, 75005 Paris, France; 10EA7285, Université de Versailles, Saint-Quentin-en-Yvelines, 78000 Versailles,
    [Show full text]
  • Evaluation of KIF23 Variant 1 Expression and Relevance As A
    Sun et al. BMC Cancer (2015) 15:961 DOI 10.1186/s12885-015-1987-1 RESEARCHARTICLE Open Access Evaluation of KIF23 variant 1 expression and relevance as a novel prognostic factor in patients with hepatocellular carcinoma Xiaotong Sun1†, Zhongtian Jin2†, Xiao Song1, Jingjing Wang1, Yan Li1, Xiaoping Qian1, Yu zhang1 and Yanhui Yin1* Abstract Background: KIF23 (kinesin family member 23) is a kinesin-like motor protein and plays an important role in cytokinesis. In search for genes associated with hepatocellular carcinoma (HCC) by cDNA microarray, we found that KIF23 was upregulated in HCC tissues. At present, much less is known about its expression and functions in tumor cells. In this work, we aimed to investigate the expression of KIF23 in HCC and the correlation between its expression and clinical features. Methods: Total RNA was extracted from 16 HCC and paired adjacent non-cancerous tissues. The expressions of the two KIF23 splice variants (KIF23 V1 and KIF23 V2) in normal and HCC tissues were determined by reverse transcriptase polymerase chain reaction (RT-PCR). Polyclonal antibody specific to KIF23 V1 was prepared, and the specificity of the antibody was confirmed by siRNA knockdown and Western blotting experiments. KIF23 protein expression in HCC was examined by immunohistochemistry staining with anti-KIF23 V1 or anti-KIF23 (commercially available for recognizing both KIF23 V1 and V2) antibodies, respectively. Univariate and Multivariate Cox regression analyses were used to determine the correlation between KIF23 protein expression and overall survival of HCC patients. Results: The two splicing variants of KIF23 mRNA were not detected in normal liver tissue by RT-PCR, but they were aberrantly expressed in HCC tissues.
    [Show full text]